Last $35.55 USD
Change Today +1.36 / 3.98%
Volume 397.7K
INSY On Other Exchanges
Symbol
Exchange
Frankfurt
As of 8:10 PM 08/22/14 All times are local (Market data is delayed by at least 15 minutes).

insys therapeutics inc (INSY) Snapshot

Open
$33.62
Previous Close
$34.19
Day High
$35.79
Day Low
$33.24
52 Week High
03/4/14 - $57.91
52 Week Low
08/27/13 - $18.27
Market Cap
1.2B
Average Volume 10 Days
689.7K
EPS TTM
$1.99
Shares Outstanding
34.5M
EX-Date
--
P/E TM
17.9x
Dividend
--
Dividend Yield
--
Current Stock Chart for INSYS THERAPEUTICS INC (INSY)

Related News

No related news articles were found.

insys therapeutics inc (INSY) Related Businessweek News

No Related Businessweek News Found

insys therapeutics inc (INSY) Details

Insys Therapeutics, Inc., a commercial-stage specialty pharmaceutical company, develops and commercializes supportive care products. It focuses on utilizing its proprietary formulation technologies to address the clinical shortcomings of existing commercial pharmaceutical products. The company markets Subsys, a proprietary sublingual fentanyl spray for breakthrough pain in opioid-tolerant cancer patients; and Dronabinol Oral Solution, a proprietary orally administered liquid formulation of dronabinol. It offers its Subsys through its incentive-based commercial sales force. The company also provides Dronabinol SG Capsule, a generic equivalent to Marinol (dronabinol), an approved second-line treatment for chemotherapy-induced nausea and vomiting, and anorexia associated with weight loss in patients with AIDS. Insys Therapeutics, Inc. was incorporated in 1990 and is headquartered in Chandler, Arizona.

266 Employees
Last Reported Date: 08/12/14
Founded in 1990

insys therapeutics inc (INSY) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $1.0M
Chief Financial Officer and Principal Account...
Total Annual Compensation: $337.9K
Compensation as of Fiscal Year 2013.

insys therapeutics inc (INSY) Key Developments

Insys Therapeutics Submits NDA for its New Oral Formulation of Dronabinol

Insys Therapeutics, Inc. announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its proprietary Dronabinol Oral Solution for anorexia associated with weight loss in patients with AIDS; and nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments. Dronabinol Oral Solution is an orally administered liquid formulation of the pharmaceutical cannabinoid dronabinol, a synthetic version of tetrahydrocannabinol (THC). Insys conducts cannabinoid research and production in the United States at its advanced pharmaceutical-grade manufacturing facility, which is approved by the DEA and inspected by the FDA. The company is expanding its production capabilities to include an additional facility to meet anticipated demand once the FDA approves its pipeline products.

INSYS Therapeutics, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

INSYS Therapeutics, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, net revenue was $55,696,000 against $18,821,000 a year ago. Income from operations was $15,186,000 against $5,188,000 a year ago. Income before income taxes was $15,212,000 against $4,922,000 a year ago. Net income was $9,465,000 or $0.26 per diluted share against $4,547,000 or $0.17 per diluted share a year ago. EBITDA was $15,770,000 against $5,630,000 a year ago. Adjusted EBITDA was $21,501,000 against $6,975,000 a year ago. Adjusted income before income taxes was $20,943,000 against $6,529,000 a year ago. Adjusted net income was $20,943,000 against $6,154,000 a year ago. Adjusted net income per diluted share was $0.58 against $0.24 a year ago. For the six months, net revenue was $97,332,000 against $29,880,000 a year ago. Income from operations was $27,855,000 against $6,008,000 a year ago. Income before income taxes was $27,900,000 against $5,065,000 a year ago. Net income was $17,123,000 or $0.47 per diluted share against $4,690,000 or $0.23 per diluted share a year ago. EBITDA was $28,964,000 against $6,875,000 a year ago. Adjusted EBITDA was $37,151,000 against $9,279,000 a year ago. Adjusted income before income taxes was $36,087,000 against $8,369,000 a year ago. Adjusted net income was $36,087,000 against $7,994,000 a year ago. Adjusted net income per diluted share was $0.99 against $0.39 a year ago.

INSYS Therapeutics, Inc., Q2 2014 Earnings Call, Aug 12, 2014

INSYS Therapeutics, Inc., Q2 2014 Earnings Call, Aug 12, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
INSY:US $35.55 USD +1.36

INSY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Galena Biopharma Inc $2.15 USD -0.05
Medivation Inc $84.44 USD -0.89
View Industry Companies
 

Industry Analysis

INSY

Industry Average

Valuation INSY Industry Range
Price/Earnings 24.7x
Price/Sales 7.3x
Price/Book 10.1x
Price/Cash Flow 23.2x
TEV/Sales 7.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INSYS THERAPEUTICS INC, please visit www.insysrx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.